Tumor imaging in vivo is one of the most active research fields, and several imaging modalities such as positron emission tomography (PET), [1] [2] [3] magnetic resonance (MR) imaging 4, 5 and fluorescence imaging techniques [6] [7] [8] [9] [10] have been extensively investigated. All these modalities use appropriate contrast reagents which are composed of signaling agents and tumortargeting molecules such as antibodies, peptides, smallmolecule ligands, or synthetic graft copolymers. One of the central problems associated with these conventional tumortargeted imaging methods, however, is the fact that the signal contrast between tumor and surrounding tissues relies on the efficient targeting to the tumor and the rapid sequestration or excretion of unbound agent. For instance, highly specific monoclonal antibodies or ligands for receptors on the surface of cancer cells, which are tagged by radioisotopes or gadolinium chelates, are used as contrast agents for PET imaging and for MR imaging, respectively. However, when such complexes are employed as imaging probes, much of the administered probes will not reach the tumor site, so a considerable amount of unbound probe remains in the blood and extracellular space of non-target tissues. Since the imaging beacons attached to the targeting antibody or ligands have constant signals, unbound probes produce a large amount of background signal which hamper high tumor-to-nontumor ratio imaging.
Among these modalities, only fluorescence imaging technique has an unique feature, in that great signal amplification can be achieved which potentially leads to the selective imaging of cancer with higher tumor-to-nontumor ratio. From this point of view, fluorescence imaging technique should have great advantages for visualizing small cancer foci in the endoscopic examination and for the assistance in surgical operation. In this article, some examples of fluorescence cancer imaging based on the novel strategies with using precisely designed and highly activatable fluorescence probes will be reviewed.
Fluorescence-based detection techniques are now commonly used for visualizing cellular processes (e.g. calcium ion, enzymes, pH, reactive oxygen species). For example, the important role of calcium ion as a second messenger in living cells would not have been elucidated without the use of calcium-sensitive fluorescence probes such as fluo-3.
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The fluorescence intensity of fluo-3 is relatively weak until it is "activated" after binding to calcium ions, whereupon the activation ratio reaches 36 -40. Nevertheless, to date there are relatively few examples of activatable fluorescence probes for in vivo imaging. Weissleder and his coworkers reported a pioneering work in that they developed activatable cyaninebased fluorescence probes which are digested by cathepsins, resulting in a loss of self-quenching and emission of signal from the released cyanine dyes. [12] [13] [14] In tumor-bearing mice, these agents produced signals only in cathepsin-secreting tumors, which afforded in vivo molecular optical imaging of tumors. This agent was based on a synthetic graft copolymer that accumulates due to the enhanced permeability and retention (EPR) effects of tumor neovasculature. Activation resulted in a 12-fold increase in NIR fluorescent signal of tumors compared to background, enabling the detection of tiny tumors.
However, their activation ratio was not satisfactory, compared to ordinary fluorescence probes for cellular experiments. Therefore, there still remains big room for the improvement of fluorescence-based tumor imaging agents. Very recently, we have succeeded in constructing a novel strategy to visualize tumors with much higher activation ratios by using novel and precisely designed fluorescence probes. 15 Hereafter, I would like to introduce our recent results.
As chemical tools for visualizing cellular processes, suitable fluorescence probes are naturally of critical importance, but only a very limited range of biomolecules can currently be visualized because of the lack of flexible design strategies for fluorescence probes. Recently, we demonstrated that the fluorescein molecule, which has been widely employed as a core of fluorescence probes, could be understood as a directly linked electron donor-fluorophore acceptor system (Fig. 1a) . 16 In other words, we could easily control and anticipate the fluorescence properties of fluorescein derivatives by using the Selective and sensitive tumor imaging in vivo is one of the most requested methodologies in medical sciences. Although several imaging modalities have been developed including positron emission tomography (PET) and magnetic resonance (MR) imaging for the detection of tumors, none of these modalities can activate the signals upon being accumulated or uptaken to tumor sites. Among these modalities, only optical fluorescence imaging has a marked advantage, that is, their signals can be dramatically increased upon detecting some biological features. In this short review, I will introduce some recent strategies for activatable optical fluorescence imaging of tumors, and discuss their advantages over other modalities. E-mail: urano@mol.f.u-tokyo.ac.jp concept of intramolecular photoinduced electron transfer (PeT). 17 So far we could develop the following novel fluorescence probes: (a) DPAXs and DMAXs 18 for singlet oxygen, (b) DAFs and DAMBOs 19 for nitric oxide, (c) HPF and APF for highly reactive oxygen species, 20 and (d) NiSPYs for peroxynitrite. 21 We next focused on the role of the carboxylic group of fluorescein. Almost all currently known fluorescein derivatives contain the carboxylic group. However, in the light of the above our photo-physical findings, the carboxylic group could be replaced with another functional group. Here we report the novel fluorescein derivatives, dubbed TokyoGreen, by breaking out of the traditional structure of fluorescein which has methyl or methoxy group instead (Fig. 1b) . TokyoGreen dyes could be easily synthesized in high yields by the conventional C-C bond coupling reaction.
Further, by precisely controlling the oxidation potential of benzene moiety, we could construct the first and totally rational design strategy for novel fluorescence probes. The value of this approach is exemplified by its application to develop a novel, highly sensitive and membranepermeable fluorescence probe for β-galactosidase 22 and alkaline phosphatase, 23 which are widely used reporter enzymes (Fig.  1c) . Using this novel fluorescence probe for β-galactosidase, called TG-βGal, we started a project for visualizing small cancer foci with high signal contrast.
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ANALYTICAL SCIENCES JANUARY 2008, VOL. 24 Peritoneal dissemination of cancer was chosen as a target, because it is known to be difficult to treat and is often fatal. During surgery, it is difficult to detect small imbedded tumors in the peritoneum due to its complex anatomy and the poor visual contrast between the tumor and normal tissue using white light imaging. Recently, we found that a lectin (asialo-receptor family)-targeted optical imaging technique which utilizes a fluorescein-avidin conjugate was effective for the visualization of peritoneal implants in a mouse ovarian cancer model. 24 We next thought that we could visualize imbedded tumors in the peritoneum more selectively and sensitively by the combination of the lectin-targeted strategy and the activatable fluorescence probes. We took a two-step procedure in that a lectin is used to localize β-galactosidase to cancer cells as an activating enzyme, and subsequent administration of a highly-sensitive fluorescence probe for the enzyme would afford remarkable fluorescence activation in tumor mass (Fig. 2a) . For this purpose, we developed a novel activatable fluorescence probe for targeted tumor imaging (AM-TG-βGal) that dramatically increases fluorescence emission when the tumor is pre-labeled with β-galactosidase as an activating enzyme. AM-TG-βGal has an additional esterase-sensitive moiety which ensures that the resulting highly fluorescent products are not easily leaked out from the cancer cells (Fig. 2b) . We used avidin-β-galactosidase as a targeting and activating enzyme conjugate, and injected it into the peritoneum one day before the administration of the fluorescence probe, AM-TG-βGal. One hour after the injection of AM-TG-βGal into peritoneum cavity, fluorescent spectral unmixed images of green fluorescence originated from TokyoGreen fluorophore were taken. As shown in Fig. 2c , clear and high tumor-to-nontumor ratio images could be obtained. 15 Further, the importance of the esterase-cleavable moiety of AM-TG-βGal could be proved by comparing the results with TG-βGal which has no esterasecleavable moiety, meaning that the resulting highly fluorescent product would be easily leaked out from the cancer cells. Since the tumor-targeted enzyme can catalyze numerous substrate turnovers, a great number of fluorescent molecules could be produced and hence the rapid and sensitive detection of tumor in vivo with high tumor-to-nontumor ratio could be achieved. We could see strong fluorescence only at tumor mass by incubating with AM-TG-βGal for 1 h when the tumor is prelabeled with β-galactosidase. Moreover, the consequent closeup investigation using fluorescence microscopy revealed that cancer microfoci as small as 200 μm could be visualized.
In conclusion, owing to the precise controlling and confinement of fluorescence activation, small tumors could be visualized without the need of waiting for complete draining of the untargeted probe that was always considered in the conventional methods. Further, fluorescence imaging methodology can be easily introduced to clinical medicine because it does not need special and expensive instruments. In the near future, highly activatable fluorescence strategies must be recognized as one of the most practical and efficient methods for visualizing small tumors with high sensitivity and selectivity.
